Abstract: The invention relates to the area of the chemical-pharmaceutical industry and medicine, in particular, to an agent for treatment of dependence on ethyl alcohol and/or drugs, treatment of psychosomatic and neurological complications in such patients; to pharmaceutical compositions containing this agent; and to treatment methods for psychosomatic and neurological complications with this agent. The aim of the invention is to develop a new pharmaceutical agent with minimal side effects. The proposed therapeutic substance, for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in such patients, which is presented by polyprenols of formula (1) where n=8-20. Therapeutic composition for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in patients is suggested, which includes an effective amount of polyprenols of formula (1) where n=8-20.

Abstract: The invention belongs in the field of medicine and can be used in the treatment of chronic and asymptomatic trichomonas infections of the urogenital tract. The invention is consisted in development of new therapeutic substance of plant origin with minimal side effects for treatment of various forms of trichomonad infection. The new therapeutic substance, of plant origin, is an olive coloured paste. It is composed of a conifer green needle complex (CGNC) and has a coniferous smell and antiprotozoal activity against Trichomonas vaginalis (when tested in an in vitro model). At a concentration of 100 mg/ml CGNC has trichomonadocitic and trichomonadostatic properties. At 300 mg/ml it suppresses the growth of T. vaginalis and at 500 mg/ml it kills this organism.

Abstract: The invention relates to the area of the chemical-pharmaceutical industry and medicine, in particular, to an agent for treatment of dependence on ethyl alcohol and/or drugs, treatment of psychosomatic and neurological complications in such patients; to pharmaceutical compositions containing this agent; and to treatment methods for psychosomatic and neurological complications with this agent. The aim of the invention is to develop a new pharmaceutical agent with minimal side effects. The proposed therapeutic substance, for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in such patients, which is presented by polyprenols of formula (1) where n=8-20. Therapeutic composition for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in patients is suggested, which includes an effective amount of polyprenols of formula (1) where n=8-20.

Abstract: The invention relates to an area of the chemical-pharmaceutical industry and medicine, particularly to an agent for treatment of dementias, including Alzheimer's disease (AD), as well as to a method of treatment and pharmaceutical composition, which is effective for both treatment of dementias, including AD or dementias of Alzheimer type, and during manifestations of the first symptoms of memory disorder. The given invention consists of the development of a new therapeutic substance with minimal side effects that currently is a topical issue for treatment of the corresponding diseases. Attached is the use of polyprenols of formula (1) where n=8-20 as an active ingredient for the production of the therapeutic agent for the treatment of patients with dementia syndrome, including those who suffer from Alzheimer's disease. It is proposed to use a therapeutic agent for the treatment of patients with dementia syndrome, including those suffering from Alzheimer's disease, being polyprenols of formula (1).

Abstract: The inventive method for processing vegetable raw materials consisting in organic solvent-extracting said materials, isolating it by retention which is associated with cooling and wax filtration, separating free oxides from the thus obtained solution of extractive substances by alkali solution action, dividing the obtained neutralized solution into a neutral substance solution in the hydrocarbon solvent and a water-alkali solution of organic acid salts, acidifying said salt solution, isolating chlorophilline acids and a fatty and resin acid fraction therefrom by retention, dividing the sum of diterpenic and higher fatty acids, distilling the solvent from neutral substances and in dividing said neutral substances. The diterpenic and higher fatty acid sum is treated in a low-molecular alcohol by adding a sulphuric acid in the form of a catalyst.

Abstract: The invention relates to the chemical and pharmaceutical industry and to medicine, in particular, to medicinal agents based on a mixture of natural oligomers of isoprenol (Ropren), which inhibits monoamine oxidase (MAO) activity; and to a method for treatment of patients suffering from diseases associated with the excessive activity of monoamine oxidase. The given invention consists of the development of a new therapeutic substance with minimal side effects that is currently a topical issue for treatment of the corresponding diseases. The proposed: Therapeutic substance consisted of polyprenols of formula (1) for treatment of patients with diseases associated with excessive activity of monoamine oxidase. with content of polyprenols of formula (1) in the given therapeutic substance from 0.1 to 80%.

Abstract: The invention belongs in the field of medicine and can be used in the treatment of chronic and asymptomatic trichomonas infections of the urogenital tract. The invention is consisted in development of new therapeutic substance of plant origin with minimal side effects for treatment of various forms of trichomonad infection. The new therapeutic substance, of plant origin, is an olive coloured paste. It is composed of a conifer green needle complex (CGNC) and has a coniferous smell and antiprotozoal activity against Trichomonas vaginalis (when tested in an in vitro model). At a concentration of 100 mg/ml CGNC has trichomonadocitic and trichomonadostatic properties. At 300 mg/ml it suppresses the growth of T. vaginalis and at 500 mg/ml it kills this organism.

Abstract: The invention belongs to the area of medicine and can be used as a therapeutic substance and as an inhibitor of the growth of Helicobacter pylori during anti-helicobacter therapy. The invention targets the development of a new therapeutic substance that does not cause adverse reactions or side effects in the liver, blood and other organs and is capable of suppressing H. Pylori growth and the progression of infection. Chlorophyll-carotene paste (CGNC) is used as an active ingredient of the pharmaceutical composition for anti-helicobacter therapy, Bioeffective A. It is an inhibitor of H. pylori. CGNC can be included as a therapeutic substance in anti-helicobacter therapy. The pharmaceutical composition for anti-helicobacter therapy contains a therapeutically effective amount of chlorophyll-carotene paste and pharmaceutically acceptable carriers and/or solvents. The pharmaceutical mixture is in the form of solution, suspension, capsule, or tablets.

Abstract: The invention relates to the area of the chemical-pharmaceutical industry and medicine, in particular, to an agent for treatment of dependence on ethyl alcohol and/or drugs, treatment of psychosomatic and neurological complications in such patients; to pharmaceutical compositions containing this agent; and to treatment methods for psychosomatic and neurological complications with this agent. The aim of the invention is to develop a new pharmaceutical agent with minimal side effects. The proposed therapeutic substance, for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in such patients, which is presented by polyprenols of formula (1) Therapeutic composition for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in patients is suggested, which includes an effective amount of polyprenols of formula (1) and pharmaceutically acceptable excipients, including carriers, and/or solvents.

Abstract: The invention relates to the chemical and pharmaceutical industry and to medicine, in particular, to medicinal agents based on a mixture of natural oligomers of isoprenol (Ropren), which inhibits monoamine oxidase (MAO) activity; and to a method for treatment of patients suffering from diseases associated with the excessive activity of monoamine oxidase. The given invention consists of the development of a new therapeutic substance with minimal side effects that is currently a topical issue for treatment of the corresponding diseases. The proposed: Therapeutic substance consisted of polyprenols of formula (1) for treatment of patients with diseases associated with excessive activity of monoamine oxidase. with content of polyprenols of formula (1) in the given therapeutic substance from 0.1 to 80%.